Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics develops and commercializes medicines for children and adults with rare disorders, with a life-science business focused on clinically differentiated therapies in areas including neurology and metabolism. Company news commonly covers product revenue, commercial launch activity, financial guidance, investor presentations, and updates from its rare-disease development portfolio.
Recurring developments include Sephience™ (sepiapterin) launch and revenue updates, clinical and regulatory disclosures involving votoplam, vatiquinone and Translarna™ (ataluren), and partnership-related program responsibilities. PTC also reports governance changes and Nasdaq inducement equity grants tied to employee compensation.
PTC Therapeutics (NASDAQ: PTCT) approved an inducement equity award on Jan. 2, 2026 granting 300 restricted stock units (RSUs) to a new non-executive employee. Each RSU represents the right to one share of common stock upon vesting. The award was approved by the company's Compensation Committee and made under the Nasdaq inducement grant exception (Listing Rule 5635(c)(4)) as part of the employee's hire compensation. The RSUs vest over four years, with 25% vesting on each annual anniversary of the hire date, subject to continued service through each vesting date.
PTC Therapeutics (NASDAQ: PTCT) announced MHLW approval of Sephience (sepiapterin) in Japan for the treatment of children and adults living with phenylketonuria (PKU).
The Japanese label covers all ages and the full spectrum of disease severity. This is PTC's first product approval in Japan and follows approvals in the EU and US within less than six months, enabling a coordinated global launch. PTC said pricing discussions in Japan are expected to conclude in Q1 2026, with commercial launch occurring shortly thereafter.
PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved Dec. 16, 2025 for five new employees under Nasdaq Listing Rule 5635(c)(4).
The company granted non-statutory stock options to purchase an aggregate of 3,825 shares and 4,385 restricted stock units (RSUs). Options have an exercise price of $75.42 (closing price on Dec. 16, 2025), a 10-year term, and vest over four years (25% after one year, then 6.25% quarterly). RSUs vest over four years with 25% vesting on each annual anniversary, subject to continued service.
PTC Therapeutics (NASDAQ: PTCT) announced that CEO Matthew B. Klein, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026 at 9:00 a.m. PST / 12:00 p.m. EST.
The presentation will be webcast live on the company’s Events and Presentations investor page at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved Nov. 24, 2025, to 15 new employees under Nasdaq Listing Rule 5635(c)(4).
The company approved non-statutory stock options to purchase an aggregate of 2,000 shares and 8,200 restricted stock units (RSUs). Options have an exercise price of $79.83 (closing price on Nov. 24, 2025), a 10-year term, and vest over four years: 25% at first anniversary then 6.25% each subsequent three months. RSUs vest over four years with 25% on each annual anniversary. Grants were approved by the Compensation Committee and issued as inducements material to each hire's acceptance of employment.
Gildan (NYSE: GIL) and several companies will move between S&P indices effective late November–early December 2025. Sandisk (SNDK) is being added to the S&P 500 on November 28, 2025, with PTC Therapeutics (PTCT) joining the S&P SmallCap 600 the same day. Upwork (UPWK) and First Interstate BancSystem (FIBK) also join the SmallCap 600 on November 28 and December 2, 2025, respectively; Interpublic, Premier and Hanesbrands will be removed.
PTC Therapeutics (NASDAQ: PTCT) will host an R&D Day on Dec. 2, 2025 at 9:30 a.m. EST in New York City, with a live webcast and replay available for ~30 days.
CEO Matthew B. Klein, M.D., and R&D leaders will present updates on the company’s proprietary small molecule splicing and inflammation platforms, including new targets and programs. Investors can register and access the webcast via the Events and Presentations page in the company’s Investor website.
PTC Therapeutics (NASDAQ: PTCT) reported Q3 2025 total revenue of $211.0M and positive net income of $15.9M. The company initiated the global launch of Sephience (sepiapterin), recording $19.6M in Sephience revenue, 521 US patient start forms from 141 prescribers, and 341 patients on commercial therapy worldwide as of September 30, 2025.
Third-quarter product revenue was $131.0M with royalty and collaboration revenue of $80.1M (including $70.8M royalty from Evrysdi). Cash, cash equivalents and marketable securities were $1.688B at quarter end. PTC narrowed full-year 2025 revenue guidance to $750–$800M and projects GAAP R&D and SG&A of $805–$835M (non-GAAP $730–$760M).
PTC Therapeutics (NASDAQ: PTCT) announced executive presentations at three investor conferences: UBS Global Healthcare Conference on Nov 11, 2025 at 3:30 p.m. EST, Jefferies Global Healthcare Conference on Nov 18, 2025 at 8:00 a.m. GMT / 3:00 a.m. EST, and Citi 2025 Global Healthcare Conference on Dec 4, 2025 at 10:30 a.m. EST.
All presentations will be webcast live and archived for 30 days on PTC's Investor Events and Presentations page. Users are advised to connect to the webcast several minutes early to ensure a timely connection.
PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved Oct. 23, 2025 for two new employees under Nasdaq Listing Rule 5635(c)(4).
The company granted non-statutory stock options to purchase an aggregate of 2,000 shares and 1,990 restricted stock units (RSUs). Options have an exercise price of $66.80 (closing price on Oct. 23, 2025), a 10-year term, and vest over four years: 25% at the first anniversary then 6.25% quarterly thereafter. RSUs vest over four years with 25% vesting on each annual anniversary. Grants were approved by the Compensation Committee and made as inducements to accept employment.